Compare Quest Diagnostics Inc (DGX) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Cassava Sciences Inc — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Quest Diagnostics Inc is far larger — about 646.7× Cassava Sciences Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Cassava Sciences Inc for 37 Days on average.
| DGX | FLNA | |
|---|---|---|
Market Cap | $25.48B | $39.40M |
Volume | 941,866 | 759,018 |
Sector | Health | Health |
52-Week High | $247.45 | $4.64 |
52-Week Low | $173.49 | $0.68 |
Typical Hold Time | 56 Days | 37 Days |
Enterprise Value | $31.23B | -$43.28M |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.
While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
